1 Introduction
1.1.1 Prevalence of the Uterine Fibroids in U.S. 8
2 Scope of Study
2.1 Research Objective 10
2.2 Assumptions & Limitations 10
2.2.1 Assumptions 10
2.2.2 Limitations 10
2.3 Market Structure 11
3 Research Methodology
3.1 Primary Research 13
3.2 Secondary Research 13
4 U.S. Uterine Fibroid Market
4.1 Introduction 15
4.2 U.S. Uterine Fibroid Market, By Type 17
4.3 U.S. Uterine Fibroid Market, By Diagnosis 19
4.4 U.S. Uterine Fibroid Market, By Treatment 21
5 Company Profile
5.1 AstraZeneca 29
5.1.1 Company Overview 29
5.1.2 Product overview 29
5.1.3 Financial Overview 30
5.1.4 Key Development 31
5.1.5 SWOT Analysis 32
5.2 Cook Medical Inc. 33
5.2.1 Overview 33
5.2.2 Product Overview 33
5.2.3 Financials 33
5.2.4 Key Developments 33
5.2.5 SWOT Analysis 34
5.3 Boston Scientific Corporation 35
5.3.1 Company Overview 35
5.3.2 Product/Business Segment Overview 35
5.3.3 Financial Overview 35
5.3.4 Key Development 36
5.3.1 SWOT Analysis 37
5.4 GE Healthcare 38
5.4.1 Company Overview 38
5.4.2 Product/Business Segment Overview 38
5.4.3 Financial Overview 38
5.4.4 Key Development 40
5.4.5 SWOT Analysis 40
5.5 AbbVie Inc. 41
5.5.1 Company Overview 41
5.5.2 Product/Business Segment Overview 41
5.5.3 Financial Overview 41
5.5.4 Key Development 43
5.5.5 SWOT Analysis 43
5.6 Hologic, Inc. 44
5.6.1 Company Overview 44
5.6.2 Product/Business Segment Overview 44
5.6.3 Financial Overview 44
5.6.4 Key Development 46
5.6.5 SWOT Analysis 46
6 List of Tables
TABLE 1 U.S. UTERINE FIBROID MARKET, BY TYPE, 2020-2027 (USD MILLION) 18
TABLE 2 U.S. UTERINE FIBROID MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 20
TABLE 3 U.S. UTERINE FIBROID MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 23
TABLE 4 U.S. UTERINE FIBROID MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION) 24
TABLE 5 PIPELINE PRODUCTS FOR UTERINE FIBROIDS 27
TABLE 6 ASTRAZENECA: KEY DEVELOPMENT 31
TABLE 7 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENT 36
TABLE 8 GE HEALTHCARE: KEY DEVELOPMENT 40
TABLE 9 ABBVIE INC.: KEY DEVELOPMENT 43
TABLE 10 HOLOGIC INC.: KEY DEVELOPMENT 46
7 List of Figures
FIGURE 1 COMPARISON BETWEEN DIAGNOSIS & TREATMENT MARKET, 2020-2027 (USD MILLION) 9
FIGURE 2 U.S. UTERINE FIBROID MARKET: MARKET STRUCTURE 11
FIGURE 3 RESEARCH PROCESS 12
FIGURE 4 U.S. UTERINE FIBROID MARKET, BY TYPE, 2023-2032 (USD MILLION) 18
FIGURE 5 U.S. UTERINE FIBROID MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 20
FIGURE 6 TREATMENTS FOR UTERINE FIBROIDS 22
FIGURE 7 U.S. UTERINE FIBROID MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 23
FIGURE 8 U.S. UTERINE FIBROID MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 24
FIGURE 9 PHARMACOTHERAPY TREATMENT FORECAST, 2020-2027 26
FIGURE 10 ASTRAZENECA: RECENT FINANCIAL 30
FIGURE 11 ASTRAZENECA: GEOGRAPHICAL MIX 30
FIGURE 12 ASTRAZENECA: OPERATING SEGMENTS 31
FIGURE 13 ASTRAZENECA: SWOT ANALYSIS 32
FIGURE 14 BOSTON SCIENTIFIC CORPORATION: RECENT FINANCIAL 35
FIGURE 15 BOSTON SCIENTIFIC CORPORATION: RECENT FINANCIAL 36
FIGURE 16 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS 37
FIGURE 17 GE HEALTHCARE: RECENT FINANCIAL 38
FIGURE 18 GE HEALTHCARE: GEOGRAPHICAL MIX 39
FIGURE 19 GE HEALTHCARE: OPERATING SEGMENTS 39
FIGURE 20 GE HEALTHCARE: SWOT ANALYSIS 40
FIGURE 21 ABBVIE INC.: RECENT FINANCIAL 41
FIGURE 22 ABBVIE INC.: GEOGRAPHICAL MIX 42
FIGURE 23 ABBVIE INC: OPERATING SEGMENTS 42
FIGURE 24 ABBVIE INC.: SWOT ANALYSIS 43
FIGURE 25 HOLOGIC INC.: RECENT FINANCIAL 44
FIGURE 26 HOLOGIC INC: GEOGRAPHICAL MIX 45
FIGURE 27 HOLOGIC INC: OPERATING SEGMENTS 45
FIGURE 28 HOLOGIC INC.: SWOT ANALYSIS 46
